IL108000A0 - N4-(substituted- oxycarbonyl) 5'-deoxy-5-fluorocytidines their preparation and pharmaceutical compositions containing them - Google Patents

N4-(substituted- oxycarbonyl) 5'-deoxy-5-fluorocytidines their preparation and pharmaceutical compositions containing them

Info

Publication number
IL108000A0
IL108000A0 IL10800093A IL10800093A IL108000A0 IL 108000 A0 IL108000 A0 IL 108000A0 IL 10800093 A IL10800093 A IL 10800093A IL 10800093 A IL10800093 A IL 10800093A IL 108000 A0 IL108000 A0 IL 108000A0
Authority
IL
Israel
Prior art keywords
radical
formula
deoxy
fluorocytidines
oxycarbonyl
Prior art date
Application number
IL10800093A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL108000(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL108000A0 publication Critical patent/IL108000A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL10800093A 1992-12-18 1993-12-13 N4-(substituted- oxycarbonyl) 5'-deoxy-5-fluorocytidines their preparation and pharmaceutical compositions containing them IL108000A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
IL108000A0 true IL108000A0 (en) 1994-04-12

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10800093A IL108000A0 (en) 1992-12-18 1993-12-13 N4-(substituted- oxycarbonyl) 5'-deoxy-5-fluorocytidines their preparation and pharmaceutical compositions containing them

Country Status (41)

Country Link
US (1) US5472949A (es)
EP (1) EP0602454B1 (es)
JP (1) JP2501297B2 (es)
KR (1) KR100347218B1 (es)
CN (1) CN1035617C (es)
AT (1) ATE137244T1 (es)
AU (1) AU671491B2 (es)
BG (1) BG61485B1 (es)
BR (1) BR9305089A (es)
CA (1) CA2103324C (es)
CZ (1) CZ284788B6 (es)
DE (1) DE69302360T2 (es)
DK (1) DK0602454T3 (es)
EE (1) EE03086B1 (es)
ES (1) ES2086856T3 (es)
FI (1) FI112365B (es)
GE (1) GEP20074251B (es)
GR (1) GR3020286T3 (es)
HK (1) HK1005875A1 (es)
HR (1) HRP931430B1 (es)
HU (2) HU218291B (es)
IL (1) IL108000A0 (es)
IS (1) IS4108A (es)
LT (1) LT3115B (es)
LV (1) LV10625B (es)
MY (1) MY109282A (es)
NO (1) NO300066B1 (es)
NZ (1) NZ250414A (es)
PH (1) PH30168A (es)
PL (1) PL174100B1 (es)
RO (1) RO112619B1 (es)
RU (2) RU2458932C2 (es)
SA (1) SA93140409B1 (es)
SI (1) SI9300648B (es)
SK (1) SK281403B6 (es)
SV (1) SV1993000080A (es)
TW (1) TW372239B (es)
UA (1) UA39158C2 (es)
UY (1) UY23697A1 (es)
YU (1) YU49411B (es)
ZA (1) ZA939293B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CN1424912A (zh) * 2000-02-28 2003-06-18 阿文蒂斯药物股份有限公司 用于治疗癌症的含有喜树碱和嘧啶衍生物的组合物
WO2001076581A1 (fr) * 2000-04-11 2001-10-18 Sayuri Yamada Compositions a base de curcumine
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
PL369670A1 (en) * 2002-01-14 2005-05-02 Novartis Ag Combinations comprising epothilones and anti-metabolites
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
CA2525973A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
DE602004015331D1 (de) * 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
EP1906977B1 (en) 2005-07-21 2012-02-22 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
MX2009011255A (es) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Proceso para preparar capecitabina.
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
ME00960B (me) 2007-06-13 2012-06-20 Incyte Corp Soli inhibitora janus kinaze, (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
RU2492860C2 (ru) 2008-06-17 2013-09-20 УАЙТ ЭлЭлСи Антиопластические комбинации, содержащие нкi-272 и винорелбин
PL3175853T3 (pl) 2008-08-04 2024-03-25 Wyeth Llc Przeciwnowotworowe połączenia neratynibu i kapecytabiny
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
PL3000467T3 (pl) 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
WO2011010967A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for producing flurocytidine derivatives
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
PL2545045T3 (pl) 2010-03-10 2016-08-31 Incyte Holdings Corp Pochodne piperydyn-4-yloazetydyny jako inhibitory JAK1
ES2584433T3 (es) 2010-03-12 2016-09-27 Genzyme Corporation Terapia de combinación para tratar cáncer de mama
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
PT2919766T (pt) 2012-11-15 2021-07-29 Incyte Corp Formas farmacêuticas de ruxolitinib de libertação controlada
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
CN116036089A (zh) 2013-08-07 2023-05-02 因赛特控股公司 Jak1抑制剂的持续释放剂型
SG11201601119XA (en) * 2013-08-20 2016-03-30 Incyte Corp Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191563A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
FI3773593T3 (fi) 2018-03-30 2024-06-18 Incyte Corp Hidradenitis suppurativan hoito jak-estäjiä käyttäen
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093A1 (en) 2022-12-05 2024-06-12 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
HUT65757A (en) 1994-07-28
ATE137244T1 (de) 1996-05-15
HRP931430A2 (en) 1998-06-30
CA2103324C (en) 1997-12-23
PH30168A (en) 1997-01-21
CN1094056A (zh) 1994-10-26
YU49411B (sh) 2006-01-16
NO300066B1 (no) 1997-04-01
LV10625B (en) 1996-04-20
IS4108A (is) 1994-06-19
NZ250414A (en) 1995-12-21
UY23697A1 (es) 1994-06-08
CA2103324A1 (en) 1994-06-19
ES2086856T3 (es) 1996-07-01
SI9300648A (en) 1994-09-30
CZ284788B6 (cs) 1999-03-17
RU2493162C1 (ru) 2013-09-20
FI935616A0 (fi) 1993-12-14
GEP20074251B (en) 2007-12-10
PL301541A1 (en) 1994-06-27
BG98304A (bg) 1994-01-03
NO934671L (no) 1994-06-20
UA39158C2 (uk) 2001-06-15
HK1005875A1 (en) 1999-01-29
HU211965A9 (en) 1996-01-29
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
CN1035617C (zh) 1997-08-13
DK0602454T3 (da) 1996-07-29
RU2458932C2 (ru) 2012-08-20
TW372239B (en) 1999-10-21
JP2501297B2 (ja) 1996-05-29
KR100347218B1 (ko) 2003-01-24
HU9303525D0 (en) 1994-04-28
CZ273193A3 (en) 1994-07-13
NO934671D0 (no) 1993-12-17
SV1993000080A (es) 1996-01-26
EP0602454B1 (en) 1996-04-24
FI935616A (fi) 1994-06-19
JPH06211891A (ja) 1994-08-02
LT3115B (en) 1994-12-27
GR3020286T3 (en) 1996-09-30
ZA939293B (en) 1994-06-18
BG61485B1 (bg) 1997-09-30
LTIP1627A (en) 1994-07-15
FI112365B (fi) 2003-11-28
SI9300648B (sl) 2000-06-30
EE03086B1 (et) 1998-04-15
SK144493A3 (en) 1994-10-05
DE69302360T2 (de) 1996-10-31
LV10625A (lv) 1995-04-20
PL174100B1 (pl) 1998-06-30
BR9305089A (pt) 1994-07-05
HU218291B (en) 2000-07-28
DE69302360D1 (de) 1996-05-30
KR940014428A (ko) 1994-07-18
YU77993A (sh) 1996-10-18
MY109282A (en) 1996-12-31
AU5069093A (en) 1994-06-30
EP0602454A1 (en) 1994-06-22
RU2135511C1 (ru) 1999-08-27
AU671491B2 (en) 1996-08-29
HRP931430B1 (en) 1999-08-31

Similar Documents

Publication Publication Date Title
IL108000A0 (en) N4-(substituted- oxycarbonyl) 5'-deoxy-5-fluorocytidines their preparation and pharmaceutical compositions containing them
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
NZ231983A (en) Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease
HU9203016D0 (en) New taxane compounds substituted with alkoxy and pharmaceutical preparatives containing these compounds
IE893653L (en) Compositions and compounds
HU9401976D0 (en) N,n'-substituted imidocarbonimidic diamides, pharmaceutical compositions containing them and use of these compounds aganst infection
SG52704A1 (en) Specamycin derivatives and the use thereof
CA2065978A1 (en) Organosilicon compounds containing (meth)acryloxy groups, their preparation and use
FR2702480B1 (fr) Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXTP Application for extension order is pending
KB Patent renewed
KB Patent renewed
EXP Patent expired